NCT06135493View on ClinicalTrials.gov

Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
DRUG

Losartan

Using losartan to prevent paclitaxel-induced peripheral neuropathy

Trial Locations (1)

Unknown

Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University, Cairo

All Listed Sponsors
lead

Future University in Egypt

OTHER

NCT06135493 - Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients | Biotech Hunter | Biotech Hunter